Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND

NCT03729401 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

39

Enrollment

OTHER

Sponsor class

Stopped Testing supplies unavailable.

Conditions

Coronary Artery Disease
Myocardial Infarction

Interventions

DRUG: Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily
DRUG: Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily
DRUG: Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily

Sponsor

Ottawa Heart Institute Research Corporation